Blueprint Medicines Corp

BPMC

NASDAQ. Currency in USD

42.97 -2.25 ( -4.98% )

Real time prices: December 19

Market Cap.
2.57B
Beta (5Y monthly)
0.62
Price/Earnings
-
EPS (TTM)
-7.69
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
587,263
1y Target Est.
78.75
Day's Range
42.33
-
45.47
52 Week's Range
40.78
-
85.67

Historical Summary

Performance
EPS growth
Share Buybacks

About Blueprint Medicines Corp

Sector
Healthcare
Industry
Biotechnology
Website
https://www.blueprintmedicines.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
58.84M
Employees
602
Address
45 Sidney Street, Cambridge, MA, United States, 02139
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Latest news

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022

Upgrades Wolfe Research upgraded the previous rating for EQT Corp (NYSE:EQT) from Peer Perform to...
By Benzinga - 6 weeks ago

Where Blueprint Medicines Stands With Analysts
Where Blueprint Medicines Stands With Analysts

Over the past 3 months, 8 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC)...
By Benzinga - 7 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?
Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We...
By Zacks Investment Research - 7 weeks ago

Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 8 weeks ago

Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take...
By Zacks Investment Research - 8 weeks ago

Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for...
By Zacks Investment Research - 9 weeks ago

Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake

HC Wainwright lowered the price target on Blueprint Medicines Corp (NASDAQ: BPMC), keeping the Buy...
By Benzinga - 12 weeks ago

Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark

Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The...
By Zacks Investment Research - 12 weeks ago